Intra-Lesional Injection of the Novel PKC Activator EBC-46 Rapidly Ablates Tumors in Mouse Models
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Intra-lesional chemotherapy for treatment of cutaneous malignancies has been used for many decades, allowing higher local drug concentrations and less toxicity than systemic agents. Here we describe a novel diterpene ester, EBC-46, and provide preclinical data supporting its use as an intra-lesional treatment. A single injection of EBC-46 caused rapid inflammation and influx of blood, followed by eschar formation and rapid tumor ablation in a range of syngeneic and xenograft models. EBC-46 induced oxidative burst from purified human polymorphonuclear cells, which was prevented by the Protein Kinase C inhibitor bisindolylmaleimide-1. EBC-46 activated a more specific subset of PKC isoforms (PKC-βI, -βII, -α and -γ) compared to the structurally related phorbol 12-myristate 13-acetate (PMA). Although EBC-46 showed threefold less potency for inhibiting cell growth than PMA in vitro, it was more effective for cure of tumors in vivo. No viable tumor cells were evident four hours after injection by ex vivo culture. Pharmacokinetic profiles from treated mice indicated that EBC-46 was retained preferentially within the tumor, and resulted in significantly greater local responses (erythema, oedema) following intra-lesional injection compared with injection into normal skin. The efficacy of EBC-46 was reduced by co-injection with bisindolylmaleimide-1. Loss of vascular integrity following treatment was demonstrated by an increased permeability of endothelial cell monolayers in vitro and by CD31 immunostaining of treated tumors in vivo. Our results demonstrate that a single intra-lesional injection of EBC-46 causes PKC-dependent hemorrhagic necrosis, rapid tumor cell death and ultimate cure of solid tumors in pre-clinical models of cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Epoxytiglianes, another class of PKC activators, showed efficacy in preclinical mouse models and clinical mast cell tumors in canine models [126, 127, 128].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [126]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening
Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, J. T., Bokesch, H., Kenney, S., & Boyd, M. R. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.13.1107 · Cited by 9,766 · cited 2×
“Serial 3-fold dilutions of the cell suspension were cultured in vitro for 6 days, and the SRB assay used to compare the growth of viable EBC-46-treated tumor cells with that of vehicle treated controls.”
MethodNormalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 1×
“This specificity may reflect the disorganization and inherent ‘‘leakiness’’ of the vasculature within a solid tumor [32].”
BackgroundIn situ detection of mycoplasma contamination in cell cultures by fluorescent Hoechst 33258 stain
Chen, T. R. (1977) · Experimental Cell Research · doi:10.1016/0014-4827(77)90089-1 · Cited by 1,700 · cited 1×
“Cells were routinely checked by STR profiling, and for mycoplasma infection by Hoechst staining [23] and PCR, and were always negative.”
MethodUse of Ly6G-specific monoclonal antibody to deplete neutrophils in mice
Daley, J. M., Thomay, A. A., Connolly, M. D., Reichner, J. S., & Albina, J. E. (2008) · Journal of Leukocyte Biology · doi:10.1189/jlb.0407247 · Cited by 1,046 · cited 1×
“Further, the anti-neutrophil antibody used here was from a different, more neutrophil-specific hybridoma clone [33] than that used in previous studies.”
ResultCorbett, T. H., Griswold, D. P., Roberts, B. J., Peckham, J. C., & Schabel, F. M. (1975) · PubMed · Cited by 584
Protein kinase C, an elusive therapeutic target?
Mochly-Rosen, D., Das, K., & Grimes, K. V. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3871 · Cited by 563 · cited 1×
“However, several clinical trials performed with compounds thought to inhibit PKC signaling have had disappointing results [9].”
BackgroundProtein kinase C: poised to signal
Newton, A. C. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00477.2009 · Cited by 512 · cited 1×
“DAG, but have been shown to be activated by distinct lipids and protein-protein interactions [5,6].”
BackgroundRegulation of vascular endothelial barrier function
Lum, H., & Malik, A. B. (1994) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.1994.267.3.l223 · Cited by 470 · cited 2×
“Activation of specific PKC isoforms in vascular endothelial cells, particularly the PKC-b isoforms, has previously been shown to induce permeability [30,31].”
BackgroundAntitumor Activity of 3-Ingenyl Angelate
Ogbourne, S. M., Suhrbier, A., Jones, B., Cozzi, S.-J., Boyle, G. M., Morris, M., McAlpine, D., Johns, J., Scott, T. M., Sutherland, K. P., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2837 · Cited by 255 · cited 2×
“We have previously demonstrated that three topical applications of the PKC-activating ingenol ester PEP005 (ingenol mebutate or ingenol 3-angelate) are sufficient for enduring regression of skin cancer lesions (including melanoma) in preclinical models [14,15].”
BackgroundSelf-citationRobertson, M. J., Kahl, B. S., Vose, J. M., de Vos, S., Laughlin, M., Flynn, P. J., Rowland, K., Cruz, J. C., Goldberg, S. L., Musib, L., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.3146 · Cited by 232 · cited 1×
“For example, enzastaurin, an orally available specific inhibitor of PKC-b, showed limited efficacy as a single agent in Phase II studies of advanced diffuse large B-cell lymphoma or non-small cell lung cancer [10,11].”
Background
Cited by
Intratumoural administration and tumour tissue targeting of cancer immunotherapies
Melero, I., Castanon, E., Alvarez, M., Champiat, S., & Marabelle, A. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00507-y · Cited by 493
Tumor microenvironment signaling and therapeutics in cancer progression
Goenka, A., Khan, F., Verma, B., Sinha, P., Dmello, C. C., Jogalekar, M. P., Gangadaran, P., & Ahn, B. (2023) · Cancer Communications · doi:10.1002/cac2.12416 · Cited by 323
Protein kinase C (PKC) isoforms in cancer, tumor promotion and tumor suppression
Isakov, N. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.04.012 · Cited by 270
“A study by Boyle and co-workers [236] tested whether intra-lesional injection of a PKC-activating diterpene ester would affect the tumor growth in intact mice.”
BackgroundDiagnosis, Prognosis and Treatment of Canine Cutaneous and Subcutaneous Mast Cell Tumors
Nardi, A. B. D., Horta, R. D. S., Fonseca‐Alves, C. E., de Paiva, F. N., Linhares, L. C. M., Firmo, B. F., Sueiro, F. A. R., de Oliveira, K. D., Lourenço, S. V., Strefezzi, R. D. F., et al. (2022) · Cells · doi:10.3390/cells11040618 · Cited by 141
Overcoming cold tumors: a combination strategy of immune checkpoint inhibitors
Ouyang, P., Wang, L., Wu, J., Tian, Y., Chen, C., Li, D., Yao, Z., Chen, R., Xiang, G., Gong, J., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1344272 · Cited by 137
“Recent advancements in cancer treatment strategies have explored the modulation of PKC signaling, utilizing activators like Bryostatins (103) and Epoxytiglianes (104 – 106), as well as inhibitors such as CGP 41251, to counteract tumor growth and reverse multidrug resistance (107).”
BackgroundNatural product-derived compounds in clinical trials and drug approvals
Butler, M. S., Capon, R. J., Blaskovich, M. A. T., & Henderson, I. R. (2026) · Natural Product Reports · doi:10.1039/d5np00031a · Cited by 98
An appraisal of natural products active against parasitic nematodes of animals
Garcia-Bustos, J., Sleebs, B. E., & Gasser, R. B. (2019) · Parasites & Vectors · doi:10.1186/s13071-019-3537-1 · Cited by 94
Antiviral Activity of Diterpene Esters on Chikungunya Virus and HIV Replication
Nothias-Scaglia, L.-F., Pannecouque, C. C., Renucci, F., Delang, L., Neyts, J. H., Roussi, F., Costa, J., Leyssen, P., Litaudon, M., & Paolini, J. (2015) · Journal of Natural Products · doi:10.1021/acs.jnatprod.5b00073 · Cited by 85
De Ridder, T. R., Campbell, J. E., Burke-Schwarz, C., Clegg, D., Elliot, E. L., Geller, S., Kozak, W., Pittenger, S. T., Pruitt, J. B., Riehl, J., et al. (2021) · Journal of Veterinary Internal Medicine · doi:10.1111/jvim.15806 · Cited by 81
“15 Intratumoral injection of TT elicits a rapid but highly localized inflammatory response, disruption of tumor vasculature, and induction of tumor cell death by oncosis.”
Self-citationSadgrove, N. J., & Jones, G. L. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.02470 · Cited by 73
“The standard tumor promoter that is used as a positive control in toxicity studies is phorbol 12myristate-13-acetate (PMA), which as the name suggests, has a fatty acid ester, substantially increasing hydrophobicity (Boyle et al., 2014).”
BackgroundEvidence for Natural Products as Alternative Wound-Healing Therapies
Moses, R. L., Prescott, T. A. K., Mas‐Claret, E., Steadman, R., Moseley, R., & Sloan, A. J. (2023) · Biomolecules · doi:10.3390/biom13030444 · Cited by 79
Equivocal, explicit and emergent actions of PKC isoforms in cancer
Parker, P. J., Brown, S. J., Calleja, V., Chakravarty, P., Cobbaut, M., Linch, M., Marshall, J. J. T., Martini, S., McDonald, N. Q., Soliman, T., et al. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00310-4 · Cited by 65
Panizza, B. J., SOUZA, P. D., Cooper, A. J., Roohullah, A., Karapetis, C. S., & Lickliter, J. D. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.11.037 · Cited by 65
“This study contributes to the body of knowledge supporting the utility of intratumoral injection as a component of local anticancer therapy and specifically to the role of PKC activation in solid tumor treatment.”
BackgroundInfluentialMinarni, M., Artika, I. M., Julistiono, H., Bermawie, N., Riyanti, E. I., Hasim, H., & Hasan, A. E. Z. (2017) · Asian Pacific Journal of Tropical Medicine · doi:10.1016/j.apjtm.2017.06.004 · Cited by 56
Powell, L. C., Cullen, J. K., Boyle, G. M., Ridder, T. R. D., Yap, P.-Y., Xue, W., Pierce, C. J., Pritchard, M., Menzies, G. E., Abdulkarim, M., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn3758 · Cited by 56
“Having observed the resolution of infection and induction of healing within dermal wounds and predicted interaction of the epoxytiglianes with the Gram-negative bacterial cell membrane, we hypothesized that the mechanism of healing reflected direct antibacterial/antibiofilm activity (Fig 1E) and the induction of the i…”
BackgroundMethodInfluentialSelf-citationMiller, J., Campbell, J., Blum, A., Reddell, P., Gordon, V., Schmidt, P., & Lowden, S. (2019) · Frontiers in Veterinary Science · doi:10.3389/fvets.2019.00106 · Cited by 50
Self-citationRanasinghe, S. L., Boyle, G. M., Fischer, K., Potriquet, J., Mulvenna, J. P., & McManus, D. P. (2018) · PLoS ONE · doi:10.1371/journal.pone.0200433 · Cited by 44
Self-citationOtsuki, K., & Li, W. (2023) · Journal of Natural Medicines · doi:10.1007/s11418-023-01713-x · Cited by 43
“Additionally, studies have compared tigilanol tiglate (18) and PMA (1), revealing that the effects of this class of compounds on tumor cells in vivo may not be linked to their effects in vitro [63].”
BackgroundInfluentialLC-MS2-Based dereplication of Euphorbia extracts with anti-Chikungunya virus activity
Nothias-Scaglia, L.-F., Dumontet, V., Neyts, J. H., Roussi, F., Costa, J., Leyssen, P., Litaudon, M., & Paolini, J. (2015) · Fitoterapia · doi:10.1016/j.fitote.2015.06.021 · Cited by 42
“In addition, EBC-46, a tigliane-type diterpene ester, was able to induce regression and ultimate cure of diverse tumors following a single intra-lesional injection in a preclinical model for cancer [41].”
BackgroundLiu, Z., Ding, Z., Chen, K., Xu, M., Yu, T., Tong, G., Zhang, H., & Li, P. (2021) · Natural Product Reports · doi:10.1039/d0np00086h · Cited by 39
Moses, R. L., Boyle, G. M., Howard-Jones, R. A., Errington, R. J., Johns, J. P., Gordon, V., Reddell, P. W., Steadman, R., & Moseley, R. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114048 · Cited by 36
Self-citationActivation of PKC supports the anticancer activity of tigilanol tiglate and related epoxytiglianes
Cullen, J. K., Boyle, G. M., Yap, P.-Y., Elmlinger, S., Simmons, J. L., Broit, N., Johns, J. P., Ferguson, B., Maslovskaya, L. A., Savchenko, A. I., et al. (2021) · Scientific Reports · doi:10.1038/s41598-020-80397-9 · Cited by 35
Self-citationWatanabe, A., Nagatomo, M., Hirose, A., Hikone, Y., Kishimoto, N., Miura, S., Yasutake, T., Abe, T., Misumi, S., & Inoue, M. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c01589 · Cited by 34
Practical synthesis of the therapeutic leads tigilanol tiglate and its analogues
Wender, P. A., Gentry, Z. O., Fanelli, D. J., Luu-Nguyen, Q. H., McAteer, O. D., & Njoo, E. (2022) · Nature Chemistry · doi:10.1038/s41557-022-01048-2 · Cited by 28
Barnett, C. M. E., Broit, N., Yap, P.-Y., Cullen, J. K., Parsons, P. G., Panizza, B. J., & Boyle, G. M. (2018) · Investigational New Drugs · doi:10.1007/s10637-018-0604-y · Cited by 27
Self-citationBrown, G. K., Campbell, J. E., Jones, P. D., Ridder, T. R. D., Reddell, P. W., & Johannes, C. M. (2021) · Frontiers in Veterinary Science · doi:10.3389/fvets.2021.675804 · Cited by 25
“There is a low likelihood of the development of resistance to TT given the host’s immune response plays a role in TT mode of action and may improve patient survival (27, 44, 45).”
BackgroundSelf-citationUse of the Intratumoural Anticancer Drug Tigilanol Tiglate in Two Horses
Ridder, T. R. D., Ruppin, M., Wheeless, M., Williams, S., & Reddell, P. W. (2020) · Frontiers in Veterinary Science · doi:10.3389/fvets.2020.00639 · Cited by 23
“This inflammatory response, mediated via cytokine and chemokine signaling, is an important component of the drug’s multifactorial mode of action and functions to isolate the tumor mass (12) and stimulate recruitment of immune cells (5).”
BackgroundResultSelf-citationReddell, P. W., Ridder, T. R. D., Morton, J. M., Jones, P. D., Campbell, J. E., Brown, G. K., Johannes, C. M., Schmidt, P. F., & Gordon, V. (2021) · Journal of Veterinary Internal Medicine · doi:10.1111/jvim.16009 · Cited by 23
Self-citationAn improved preparation of phorbol from croton oil
Pagani, A., Gaeta, S., Savchenko, A. I., Williams, C. M., & Appendino, G. (2017) · Beilstein Journal of Organic Chemistry · doi:10.3762/bjoc.13.133 · Cited by 20
Tran, T. D., Olsson, M. A., McMillan, D. J., Cullen, J. K., Parsons, P. G., Reddell, P. W., & Ogbourne, S. M. (2020) · Antibiotics · doi:10.3390/antibiotics9080487 · Cited by 19
“White, has been discovered and shown to have significant anticancer activity [7].”
BackgroundSelf-citationCurci, A., Mele, A., Camerino, G. M., Dinardo, M. M., & Tricarico, D. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00476 · Cited by 19
“The PKC isoforms particularly the alpha type, regulates physiological processes such as phagocytosis, endocytosis and desmosome downregulation; exert a cytoprotecting role against some forms of tumors (Larsen et al., 2000; Cheeseman et al., 2006; Boyle et al., 2014; McHarg et al., 2014).”
BackgroundLamont, R. W., Conroy, G., Reddell, P. W., & Ogbourne, S. M. (2016) · BMC Plant Biology · doi:10.1186/s12870-016-0743-2 · Cited by 19
“shown to result in rapid ablation and cure of tumours in pre-clinical murine models [4].”
BackgroundSelf-citationBioactive Segetane, Ingenane, and Jatrophane Diterpenes from Euphorbia taurinensis
Rédei, D., Kúsz, N., Sátori, G., Kincses, A., Spengler, G., Burián, K., Barina, Z., & Hohmann, J. (2018) · Planta Medica · doi:10.1055/a-0589-0525 · Cited by 19
“Local application of the compound causes rapid tumor ablation through hemorrhagic necrosis and tumor vasculatory destruction, supporting its use in cutaneous malignancies [4].”
BackgroundJones, P. D., Campbell, J. E., Brown, G. K., Johannes, C. M., & Reddell, P. W. (2020) · Journal of Veterinary Internal Medicine · doi:10.1111/jvim.16018 · Cited by 19
“The result is hemorrhagic necrosis and destruction of the tumor within 2 to 7 days, tumor slough by day 14, followed by resolution of the resulting wound.(2,5) The efficacy and safety of TT for intratumoral treatment of MCT in dogs have been investigated in a randomized, sham-controlled, investigator- and owner-masked…”
BackgroundSelf-citationFermaintt, C. S., Peramuna, T., Cai, S., Takahashi‐Ruiz, L., Essif, J. N., Grant, C. V., O’Keefe, B. R., Mooberry, S. L., Cichewicz, R. H., & Risinger, A. L. (2021) · Cancers · doi:10.3390/cancers13112834 · Cited by 18
Patel, B. R., & Tall, G. G. (2016) · Oncogenesis · doi:10.1038/oncsis.2016.45 · Cited by 18
Use of kinase inhibitors against schistosomes to improve and broaden praziquantel efficacy
Nawaratna, S. S. K., McManus, D. P., Gasser, R. B., Brindley, P. J., Boyle, G. M., Rivera, V., Ranasinghe, S. L., Jones, M. K., You, H., & Gobert, G. N. (2020) · Parasitology · doi:10.1017/s0031182020001250 · Cited by 16
Self-citationGrant, E. L., Conroy, G., Lamont, R. W., Reddell, P. W., Wallace, H. M., & Ogbourne, S. M. (2019) · Heredity · doi:10.1038/s41437-019-0231-1 · Cited by 16
Self-citationEn Route to D-Ring Inverted Phorbol Esters
Chow, S., Krainz, T., Bernhardt, P. V., & Williams, C. M. (2019) · Organic Letters · doi:10.1021/acs.orglett.9b03379 · Cited by 16
Cullen, J. K., Yap, P.-Y., Ferguson, B., Bruce, Z. C., Koyama, M., Handoko, H. Y., Hendrawan, K., Simmons, J. L., Brooks, K. M., Johns, J. P., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006602 · Cited by 15
“Combinatorial activity was only observed at the highest dose of TT tested in the B16- F10-OVA model (30 µg), suggesting some form of concentration dependence that may be related to the underlying mechanism of cell death induced by TT. Interestingly, more favorable abscopal responses in non-injected tumors were observe…”
BackgroundResultInfluentialSelf-citationKunitz type protease inhibitor from the canine tapeworm as a potential therapeutic for melanoma
Ranasinghe, S. L., Rivera, V., Boyle, G. M., & McManus, D. P. (2019) · Scientific Reports · doi:10.1038/s41598-019-52609-4 · Cited by 15
Self-citationChiral Pool Guided Syntheses of Polycyclic Natural Products
Fu, S., & Liu, B. (2021) · Chinese Journal of Chemistry · doi:10.1002/cjoc.202100565 · Cited by 14
Hansen, N., Nicholas, N., Pack, G., Mackie, J. T., Shipstone, M. A., Munday, J. S., Reddell, P. W., Orbell, G., & Malík, R. (2017) · Veterinary Medicine and Science · doi:10.1002/vms3.85 · Cited by 14
“…(a) an acute, short-term, highly localised pro-inflammatory response at the site of application that activates the patient’s innate immune system (Boyle et al. 2014) and (b) differential expression of genes in keratinocytes (grown in vitro) that have wellestablished roles in modulation of cell…”
BackgroundResultSelf-citationKumar, P., Mathew, S., Gamage, R. V., Bodkin, F., Doyle, K., Rosetti, I., Wagnon, I. M., Zhou, X., Raju, R., Gyengési, E., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241311086 · Cited by 13
“The drug is administered directly into the tumor site, where it appears to target the blood vessels that supply the tumor, leading to a rapid collapse of the tumor and the surrounding tissue [95,96].”
BackgroundÜner, G., Tağ, Ö., Erzurumlu, Y., Ballar, P., & Bedіr, E. (2020) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.0c00339 · Cited by 11
Neue Arzneimittel für Kleintiere 2009
Emmerich, I. U. (2010) · Tierärztliche Praxis Ausgabe K Kleintiere / Heimtiere · doi:10.1055/s-0038-1622863 · Cited by 9
Grant, E. L., Wallace, H. M., Trueman, S. J., Reddell, P. W., & Ogbourne, S. M. (2017) · Industrial Crops and Products · doi:10.1016/j.indcrop.2017.07.013 · Cited by 9
“Tigilanol tiglate (EBC-46) is a novel compound from the tropical rainforest tree, Fontainea picrosperma (Euphorbiaceae) that is being developed as a cancer therapeutic for veterinary and human markets (Boyle et al., 2014; Linkliter et al., 2015).”
BackgroundSelf-citationTreatment of multiple synchronous canine mast cell tumours using intratumoural tigilanol tiglate
Brown, G. K., Finlay, J. R., Straw, R. C., Ziea, J. Y., Leung, B., O’Connell, K. M., Thomson, M. J., Campbell, J. E., Jones, P. D., & Reddell, P. W. (2022) · Frontiers in Veterinary Science · doi:10.3389/fvets.2022.1003165 · Cited by 8
Self-citationThe P450 multigene family of Fontainea and insights into diterpenoid synthesis
Mitu, S. A., Ogbourne, S. M., Klein, A. H., Tran, T. D., Reddell, P. W., & Cummins, S. F. (2021) · BMC Plant Biology · doi:10.1186/s12870-021-02958-y · Cited by 8
Self-citationLabens, R., Saba, C., Williams, J. M., Hollis, A. R., Ensink, J. M., José‐Cunilleras, E. L. V., Jordana‐Garcia, M., Bergvall, K. E., Ruppin, M., Condon, F., et al. (2025) · Equine Veterinary Journal · doi:10.1111/evj.14502 · Cited by 7
“17,18,20,33,34,36 Adverse events nevertheless occurred and were by and large attributable to administration of excessive doses, inadequate prevention of ensuing inflammatory responses or an unexpected level of inflammation post treatment.”
Self-citationBrunton, A. J., Lamont, R. W., Conroy, G., Yap, J. S., Rossetto, M., Taylor–Brown, A., Maggia, L., Reddell, P. W., & Ogbourne, S. M. (2022) · Diversity · doi:10.3390/d14090725 · Cited by 7
Self-citationConversion of Phorbol into Des-D-Ring Tricycle and Crotonianoid B via Peroxidation Reaction
Watanabe, A., Hikone, Y., Nagatomo, M., & Inoue, M. (2024) · Organic Letters · doi:10.1021/acs.orglett.4c01363 · Cited by 7
Mitu, S. A., Cummins, S. F., Reddell, P. W., & Ogbourne, S. M. (2020) · Fitoterapia · doi:10.1016/j.fitote.2020.104680 · Cited by 7
Self-citationRidder, T. R. D., Reddell, P. W., Jones, P. D., Brown, G. K., & Campbell, J. E. (2021) · Frontiers in Veterinary Science · doi:10.3389/fvets.2021.764800 · Cited by 7
“and immune cell recruitment that are associated with the mode of action of TT (4, 5, 8, 9); (c) Anatomical location, especially in relation to the extent of the local inflammatory response and the effects on lymphatic drainage and the speed of resolution of oedema; and (d) Variability in dose administration with diffe…”
BackgroundSelf-citationNeue Arzneimittel für Kleintiere 2011
Emmerich, I. U. (2012) · Tierärztliche Praxis Ausgabe K Kleintiere / Heimtiere · doi:10.1055/s-0038-1623665 · Cited by 7
Arid awakening: new opportunities for Australian plant natural product research
Simpson, B. S., Bulone, V., Semple, S. J., Booker, G. W., McKinnon, R. A., & Weinstein, P. (2016) · The Rangeland Journal · doi:10.1071/rj16004 · Cited by 7
Neue Arzneimittel für Kleintiere 2004/2005
Emmerich, I. U., & Ungemach, F. R. (2006) · Tierärztliche Praxis Ausgabe K Kleintiere / Heimtiere · doi:10.1055/s-0037-1622536 · Cited by 7
Grant, E. L., Wallace, H. M., Brooks, P. R., Burwell, C. J., Reddell, P. W., & Ogbourne, S. M. (2021) · Ecology and Evolution · doi:10.1002/ece3.7850 · Cited by 6
“…of F. picrosperma is also of significant commercial interest because its fruit contains the small molecule natural product, tigilanol tiglate (Boyle et al., 2014), which has re - cently been approved as a veterinary oncology product as a thera - peutic for canine mast cell tumors (De Ridder…”
BackgroundSelf-citationThe allylic oxidation of tigliane esters
Amin, H. I. M., Maioli, C., Chianese, G., Appendino, G., Gaeta, S., & Taglialatela‐Scafati, O. (2020) · Fitoterapia · doi:10.1016/j.fitote.2020.104802 · Cited by 5
Cryptic Epoxytiglianes from the Kernels of the Blushwood Tree (Fontainea picrosperma)
Chianese, G., Amin, H. I. M., Maioli, C., Reddell, P. W., Parsons, P. G., Cullen, J. K., Johns, J. P., Handoko, H. Y., Boyle, G. M., Appendino, G., et al. (2022) · Journal of Natural Products · doi:10.1021/acs.jnatprod.2c00226 · Cited by 5
Self-citationChow, S., Krainz, T., Bettencourt, C. J., Broit, N., Ferguson, B., Zhu, M., Hull, K. G., Pierens, G. K., Bernhardt, P. V., Parsons, P. G., et al. (2020) · Chemistry - A European Journal · doi:10.1002/chem.202003221 · Cited by 5
Self-citationMoses, R. L., Woods, E. L., Dally, J., Johns, J. P., Knäuper, V., Boyle, G. M., Gordon, V., Reddell, P. W., Steadman, R., & Moseley, R. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116607 · Cited by 4
“Epoxytiglianes are a class of diterpene esters derived from the native Australian rainforest plant, Fontainea picrosperma [16,17].”
InfluentialSelf-citationEvolution of a Synthetic Strategy for Complex Diterpenes from Euphorbiaceae and Thymelaeaceae
Yu, K., Vasilev, V. H., Spessert, L., & Maimone, T. J. (2026) · Journal of the American Chemical Society · doi:10.1021/jacs.5c22127 · Cited by 3
Xue, W., Pritchard, M., Khan, S., Powell, L. C., Stokniene, J., Wu, J., Claydon, N., Reddell, P. W., Thomas, D. W., & Hill, K. E. (2023) · Journal of Oral Microbiology · doi:10.1080/20002297.2023.2241326 · Cited by 3
“Firstly, via direct local immune cell induction mediated by protein kinase C (PKC)- activation in both resident-(keratinocytes and fibroblasts) and migratory cells (neutrophils; PMNLs) [13,16].”
BackgroundSelf-citationResponse to tigilanol tiglate in dogs with mast cell tumors
Musser, M. L., Jones, P. D., Goodson, T. L., Roof, E., & Johannes, C. M. (2024) · Journal of Veterinary Internal Medicine · doi:10.1111/jvim.17211 · Cited by 3
Neue Arzneimittel für Kleintiere 2007
Emmerich, I. U., & Ungemach, F. R. (2008) · Tierärztliche Praxis Ausgabe K Kleintiere / Heimtiere · doi:10.1055/s-0038-1622691 · Cited by 3
Neue Arzneimittel für Kleintiere 2014
Emmerich, I. U. (2015) · Tierärztliche Praxis Ausgabe K Kleintiere / Heimtiere · doi:10.15654/tpk-150260 · Cited by 2
The use of tigilanol tiglate (Stelfonta®) for the treatment of canine mast cell tumors
Verbrugghe, A., Vos, S. D., Krupa, A., Vandenabeele, S., & de Rooster, H. (2023) · Vlaams Diergeneeskundig Tijdschrift · doi:10.21825/vdt.86336 · Cited by 2
Antwi, F. D., Awad, T., Larin, M., Heesom, K. J., Lewis, P. A., Reddell, P. W., Poghosyan, Z. P., Dewitt, S., Moseley, R., & Knäuper, V. (2024) · Cells · doi:10.3390/cells13110982 · Cited by 2
“Surprisingly, secretome analysis at 1 h showed that TT treatment had reduced protein levels in culture media when compared to DMSO controls.”
BackgroundMethodInfluentialSelf-citationIdentification of Gene Biomarkers for Tigilanol Tiglate Content in Fontainea picrosperma
Mitu, S. A., Stewart, P., Tran, T. D., Reddell, P. W., Cummins, S. F., & Ogbourne, S. M. (2022) · Molecules · doi:10.3390/molecules27133980 · Cited by 2
“It is of particular interest due to its effectiveness as a local treatment for a range of cancers in humans and animals [7,12,13].”
BackgroundSelf-citationStemmet, G. P., Parsons, P. G., Johns, J. P., Reddell, P. W., & Labens, R. (2026) · Frontiers in Veterinary Science · doi:10.3389/fvets.2026.1807796 · Cited by 1
“Even so, this inflammatory response is integral to the Frontiers in Veterinary Science 12 frontiersin.org multifactorial agnostic mode of action of tigilanol tiglate that leads to avascular oncolysis and recruitment of immune cells (2, 3, 35).”
Self-citationOnkologie und Versorgung in Fach- und Publikumsmedien
Gaisser, A. (2015) · Der Onkologe · doi:10.1007/s00761-015-2917-1 · Cited by 1
Neue Arzneimittel für Kleintiere 2017
Emmerich, I. U. (2018) · Tierärztliche Praxis Ausgabe K Kleintiere / Heimtiere · doi:10.15654/tpk-180334 · Cited by 1
Neue Arzneimittel für Kleintiere 2018
Emmerich, I. U. (2019) · Tierärztliche Praxis Ausgabe K Kleintiere / Heimtiere · doi:10.1055/a-0858-4261 · Cited by 1
Neue Arzneimittel für Kleintiere 2019
Emmerich, I. U. (2020) · Tierärztliche Praxis Ausgabe K Kleintiere / Heimtiere · doi:10.1055/a-1115-8031 · Cited by 1
Neue Arzneimittel für Kleintiere 2021
Emmerich, I. U. (2022) · Tierärztliche Praxis Ausgabe K Kleintiere / Heimtiere · doi:10.1055/a-1867-2855 · Cited by 1
Erfolgreiche lokale Behandlung eines digitalen kaninen Mastzelltumors mit Tigilanoltiglat
Gasser, K. (2022) · Tierärztliche Praxis Ausgabe K Kleintiere / Heimtiere · doi:10.1055/a-1844-8554 · Cited by 1
“Im Jahr 2014 wurde die erste Studie im Mausmodel fentlich [6], 2019 die ersten klinischen Studien beim Hund [7].”
Zi, J., Zhao, L., Zha, W., Xian, M., & Zhu, J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-18611-0.00007-3 · Cited by 1
Neue Arzneimittel für Kleintiere 2010
Emmerich, I. U. (2011) · Tierärztliche Praxis Ausgabe K Kleintiere / Heimtiere · doi:10.1055/s-0038-1623608 · Cited by 1
Erhöhen Bluttransfusionen das Rückfallrisiko bei Krebs?
Medizin-Verlag, S. (2015) · best practice onkologie · doi:10.1007/s11654-015-0287-1
Onkologie und Versorgung in Fach- und Publikumsmedien
Gaisser, A. (2013) · Der Onkologe · doi:10.1007/s00761-013-2580-3
Optimising intratumoural treatment of head and neck squamous cell carcinoma mouse models with EBC-46
Barnett, C. M. E. (2015) · The University of Queensland · doi:10.14264/uql.2015.895
“It has been established that intratumoural injection of the novel PKC-activating drug EBC46 ablates subcutaneous xenografts of 2 different human HNSCC cell lines in BALB/c Foxn1 mice [10].”
BackgroundMethodInfluentialNeue Arzneimittel für Kleintiere 2012
Emmerich, I. U. (2013) · Tierärztliche Praxis Ausgabe K Kleintiere / Heimtiere · doi:10.1055/s-0038-1623716
Neue Arzneimittel für Kleintiere 2016
Emmerich, I. U. (2017) · Tierärztliche Praxis Ausgabe K Kleintiere / Heimtiere · doi:10.15654/tpk-170278
Anticorpos conformacionais para PKCs clássicas e suas aplicações
Pena, D. A. (2016) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.46.2016.tde-17082016-074719
Dally, J. (2018) · ORCA Online Research @Cardiff (Cardiff University) · Cited by 2
The Globalization of Health Data Will Revolutionize Medicine
Chaideftos, C. (2019) · Proceedings of the International Academic Conference on Research in Social Sciences · doi:10.33422/iacrss.2019.11.638
Mastzelltumoren der Haut beim Hund – Erste Erfahrungen zum Einsatz von Tigilanoltiglat
Horn, M. (2021) · kleintier konkret · doi:10.1055/a-1327-9818
“Zurück bleibt eine Wunde, deren Größe etwa mit dem Tumorvolumen korreliert [18] (▶ Abb.”
BackgroundNeue Arzneimittel für Kleintiere 2020
Emmerich, I. U. (2021) · Tierärztliche Praxis Ausgabe K Kleintiere / Heimtiere · doi:10.1055/a-1428-7648
Estrategias terapéuticas contra el cáncer en animales de compañía
Ruiz-Castillo, D. D. J., Arroyo-León, E., & Cervantes-Arias, A. (2021) · Tequio · doi:10.53331/teq.v5i13.4031
Chaideftos, C. (2020) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/hv5cx
Cullen, J. K., Yap, P.-Y., Ferguson, B., Bruce, Z. C., Koyama, M., Handoko, H. Y., Simmons, J. L., Johns, J. P., D'Souza, M. M. A., Broit, N., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-sitc2022.1121
“injection of TT results in complete and enduring ablation of target tumours in >70% of patients.(1,2,3) TT has completed a Phase I/IIa dose-escalation trial in humans (ACTRN12614000685617), with strong evidence of local anticancer efficacy and signs of abscopal effects in some patients.”
BackgroundSelf-citationChemical and pharmacological investigations of African Euphorbia species
Hammadi, R. (2023) · SZTE Repository of Dissertations (University of Szeged) · doi:10.14232/phd.11515
Cullen, J. K., Yap, P.-Y., Ferguson, B., Bruce, Z. C., Koyama, M., Handoko, H. Y., Johns, J. P., Stewart, P., Ogbourne, S. M., Reddell, P. W., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-sitc2023.1091
Self-citationNeue Arzneimittel für Kleintiere 2023
Emmerich, I. U. (2024) · Tierärztliche Praxis Ausgabe K Kleintiere / Heimtiere · doi:10.1055/a-2291-7019
Additional file 1 of The P450 multigene family of Fontainea and insights into diterpenoid synthesis
Mitu, S. A., Ogbourne, S. M., Klein, A. H., Tran, T. D., Reddell, P. W., & Cummins, S. F. (2021) · Figshare · doi:10.6084/m9.figshare.14456930
Self-citationRecent Advances in Medical Oncology for Exotic Animal Species
Sutherland, M. W., Carrasco, D. C., Bradley, L., & Finlay, J. R. (2026) · Veterinary Clinics of North America Exotic Animal Practice · doi:10.1016/j.cvex.2025.12.004
Nothias-Scaglia, L.-F. (2015) · theses.fr (ABES) · doi:10.70675/220f96d3zc9d0z4998zaed8z84697b65f84e
Üner, G., Ulker, C., Ballar, P., & Bedіr, E. (2026) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2026.03.002
Metadata
- Authors
- Boyle, G. M., D'Souza, M. M. A., Pierce, C. J., Adams, R. A., Cantor, A. S., Johns, J. P., Maslovskaya, L., Gordon, V. A., Reddell, P. W., & Parsons, P. G.
- Affiliations
- QIMR Berghofer Medical Research Institute (AU)
- The University of Queensland (AU)
- Corresponding author
- Boyle, Glen M.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-10-01
- Volume
- 9
- Issue
- 10
- Pages
- e108887
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4182759
- OpenAlex
- W1992030745
- Cited by
- 101
- References
- 34
- Citations by year
- 2026: 6 · 2025: 2 · 2024: 8 · 2023: 10 · 2022: 10 · 2021: 14 · 2020: 13 · 2019: 9 · 2018: 5 · 2017: 6 · 2016: 4 · 2015: 6 · 2014: 1
- FWCI
- 4.29
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Funders
- University of Queensland
- Queensland Government
- Qbiotics
- Medical Research Council
- National Health and Medical Research Council (1017676)
- Topics
- Health Sciences › Medicine › Dermatology › Nonmelanoma Skin Cancer Studies
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- protein kinase C activators, intralesional chemotherapy, skin cancer, tumor ablation, diterpene esters, PKC isoforms, phorbol myristate acetate, respiratory burst, hemorrhagic necrosis, tumor vascular permeability, eschar formation, cancer cell death, pharmacokinetics
- MeSH terms
- Animals, Antineoplastic Agents, Diterpenes, Humans, Indoles, Maleimides, Neoplasms, Protein Kinase C, Injections, Intralesional, Cell Line, Tumor, Protein Kinase Inhibitors, Mice, Heterografts
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.